EVI Team Retreat: strengthening resilience and building unity
November 2024 Last week, the EVI team gathered in Frankfurt for a retreat designed to recharge, step away from our daily routines, and...
top of page
The broadly protective malaria vaccine combination
CAPTIVATE
The EU pledges €8.2 million to advance the next generation of malaria vaccines to the clinic.
Today's catalyst for tomorrow's vaccines
Since 1998, working with partners globally to develop safe, effective and affordable vaccines.
We are a science-driven organisation, leading innovative solutions for vaccine R&D through cross-cutting activities, capacity strengthening and advocacy. EVI supports vaccine R&D by taking action from three different areas:
Translational product development
Our goal is to catalyse the development of vaccines for global health. We actively engage in product development activities for new vaccine candidates and bridge early-stage vaccine candidates from discovery to early clinical trials.
Cross-cutting activities
We are committed to supporting vaccine development beyond individual vaccine candidates. We engage in initiatives aimed at creating harmonisation between stakeholders, promoting networking, developing innovative R&D solutions, and accessing vaccine infrastructure at the European and global level.
Knowledge sharing & advocacy
Our goal is to extend the benefits of vaccines to all people by improving knowledge access and uptake of vaccines.
We take active part in vaccine advocacy, and supply data and road maps that can enable decision makers to make evidence-based decisions on vaccines and immunisation.
+40 vaccine
formulations clinically tested
+200 partners worldwide
+5 disease areas
Malaria · Leishmaniasis · Diarrhoeal diseases · Emerging epidemics · AMR · Dengue
Support to +100 preclinical vaccine candidates
bottom of page